Nurix Therapeutics (NASDAQ:NRIX) Insider Gwenn Hansen Sells 1,452 Shares of Stock

Nurix Therapeutics, Inc. (NASDAQ:NRIX) insider Gwenn Hansen sold 1,452 shares of the company’s stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $25.00, for a total transaction of $36,300.00. Following the transaction, the insider owned 117,227 shares of the company’s stock, valued at approximately $2,930,675. This trade represents a 1.22% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Gwenn Hansen also recently made the following trade(s):

• On Tuesday, September 1st, Gwenn Hansen sold 1,452 shares of Nurix Therapeutics stock. The shares were sold at an average price of $25.47, for a total transaction of $36,982.44.
• On Wednesday, August 5th, Gwenn Hansen sold 4,356 shares of Nurix Therapeutics stock. The shares were sold at an average price of $25.00, for a total transaction of $108,900.00.
• On Tuesday, August 4th, Gwenn Hansen sold 4,111 shares of Nurix Therapeutics stock. The stock was sold at an average price of $24.36, for a total value of $100,143.96.
• On Thursday, July 30th, Gwenn Hansen sold 3,847 shares of Nurix Therapeutics stock. The stock was sold at an average price of $23.38, for a total value of $89,942.86.

Nurix Therapeutics Trading Up 5.4%

NASDAQ:NRIX opened at $24.95 on Friday. Nurix Therapeutics, Inc. has a 12 month low of $9.71 and a 12 month high of $28.23. The stock has a 50 day moving average of $25.13 and a two-hundred day moving average of $21.13. The firm has a market cap of $2.73 billion, a P/E ratio of 10.80 and a beta of 1.82.

Nurix Therapeutics (NASDAQ:NRIX) last released its earnings results on Monday, October 12th. The company reported $4.73 earnings per share for the quarter, beating the consensus estimate of ($0.60) by $5.33. The business had revenue of $673.06 million for the quarter, compared to the consensus estimate of $24.35 million. Nurix Therapeutics had a return on equity of 49.34% and a net margin of 42.01%. On average, research analysts forecast that Nurix Therapeutics, Inc. will post 0.85 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have weighed in on NRIX shares. Mizuho boosted their target price on shares of Nurix Therapeutics from $30.00 to $34.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Stifel Nicolaus set a $41.00 price target on shares of Nurix Therapeutics in a report on Tuesday. Needham & Company LLC restated a “buy” rating and set a $34.00 price target on shares of Nurix Therapeutics in a report on Tuesday. Wall Street Zen raised shares of Nurix Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 26th. Finally, Robert W. Baird upped their price objective on Nurix Therapeutics from $33.00 to $36.00 and gave the company an “outperform” rating in a report on Tuesday. Thirteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $34.64.

Institutional Trading of Nurix Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. General Atlantic L.P. purchased a new position in Nurix Therapeutics during the fourth quarter worth about $92,899,000. Trails Edge Capital Partners LP purchased a new position in Nurix Therapeutics during the second quarter worth about $38,166,318. Bank of New York Mellon Corp acquired a new stake in shares of Nurix Therapeutics during the second quarter valued at about $6,614,000. Man Group plc acquired a new stake in shares of Nurix Therapeutics during the second quarter valued at about $2,076,000. Finally, Baker BROS. Advisors LP increased its position in shares of Nurix Therapeutics by 20.0% during the fourth quarter. Baker BROS. Advisors LP now owns 4,658,556 shares of the company’s stock valued at $88,373,000 after acquiring an additional 776,431 shares during the last quarter.

Nurix Therapeutics News Roundup

Here are the key news stories impacting Nurix Therapeutics this week:

• Positive Sentiment: Nurix initiated the Phase 3 DAYBreak CLL-306 trial of bexobrutideg in relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. An analyst maintained a “Strong Buy” rating, citing promising earlier-stage data, potential accelerated approval and multiple development opportunities. Bexobrutideg clinical analysis
• Positive Sentiment: Analyst sentiment remains broadly bullish. Baird raised its price target to $36 and maintained an “Outperform” rating, while Needham reiterated “Buy” with a $34 target. The consensus target is approximately $34.64, above recent trading levels. Nurix analyst ratings
• Neutral Sentiment: Nurix’s quarterly results significantly exceeded estimates, with earnings of $4.73 per share versus a projected loss of $0.60 and revenue of $673.06 million versus a $24.35 million consensus estimate. However, the earnings reaction was tempered by higher operating expenses as the company continues investing in its pipeline. Nurix quarterly earnings
• Negative Sentiment: Truist reduced its price target for Nurix while retaining a “Buy” rating, signaling more cautious near-term expectations despite confidence in the company’s longer-term prospects. Truist price target update
• Negative Sentiment: Director Julia Gregory sold 22,583 shares for about $528,000, reducing her direct ownership by 67.75%. Separately, insider Gwenn Hansen sold 1,452 shares for $36,300 under a pre-arranged Rule 10b5-1 plan. While planned sales may reflect diversification or personal financial needs, the transactions can weigh on investor sentiment. Nurix insider sale filing

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a biopharmaceutical company focused on developing medicines that regulate the levels and activity of disease-causing proteins. Headquartered in San Francisco, California, the company uses its DELigase platform to discover therapies based on targeted protein degradation and immune-system modulation.

Nurix’s pipeline includes oral targeted protein degraders designed to eliminate specific proteins involved in cancer and immune-cell function. Its lead programs have included NX-5948, a Bruton’s tyrosine kinase degrader being evaluated for certain B-cell malignancies, and NX-2127, an investigational degrader designed to target BTK and other proteins relevant to cancer biology.